Abstract
Background
Morbid obesity is a state of insulin resistance combined with excess of visceral fat, which contributes to the development of metabolic syndrome (MetS). Nonsurgical treatment of obesity usually improves MetS, but there is no ultimate resolution and weight regain is common. Surgical options like Roux-en-Y gastric bypass (RYGB) and sleeve gastrectomy (SG) result in a significant and sustained weight loss accompanied by improvement of MetS. The aim of this study was to compare the weight loss and improvement of MetS parameters between degree II and III obese patients with MetS undergoing RYGB or SG in a period of 12 months.
Methods
Analysis of medical records of 102 patients diagnosed with MetS (63 undergoing RYGB and 39 undergoing SG) in a reference center (CTO ISCMPA) between 2010 and 2013.
Results
After 1-year follow-up, an excess weight loss (EWL) of 77.2 ± 22.5% and of 63.4 ± 20.1% (p = 0.033) was observed in the RYGB and SG groups, respectively. The rate of MetS resolution was very similar (87.3 and 84.6%, respectively; p = 0.971). The percentage of patients with type 2 diabetes was 3.3% for RYGB and 15.4% for SG (p = 0.025). Fasting blood glucose levels followed the same trend with mean values reaching 87.6 ± 16.9 mg/dl in the RYGB group and 97.7 ± 35.5 mg/dl in the group undergoing SG (p = 0.023).
Conclusions
Among the patients studied, both surgical techniques were safe and effective for MetS resolution in 12 months. However, RYGB was more effective for EWL and improvement of some parameters related to glucose metabolism.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
International Diabetes Federation: The IDF consensus worldwide definition of the metabolic syndrome. 2006; 1–24. Available from: http://www.idf.org/webdata/docs/IDF_Meta_def_final.pdf
McCullough AJ. Epidemiology of the metabolic syndrome in the USA. J Dig Dis. 2011;12(5):333–40.
Inabnet 3rd WB, Winegar DA, Sherif B, et al. Early outcomes of bariatric surgery in patients with metabolic syndrome: an analysis of the bariatric outcomes longitudinal database. J Am Coll Surg. 2012;214(4):550–6. discussion 556-7
Sjöström L, Peltonen M, Jacobson P, et al. Bariatric surgery and long-term cardiovascular events. JAMA. 2012;307(1):56–65.
Schauer PR, Ikramuddin S, Gourash W, et al. Outcomes after laparoscopic Roux-en-Y gastric bypass for morbid obesity. Ann Surg. 2000;232(4):515–29.
Shi X, Karmali S, Sharma AM, et al. A review of laparoscopic sleeve gastrectomy for morbid obesity. Obes Surg. 2010;20(8):1171–7.
Lee WJ, Chong K, Ser KH, et al. Gastric bypass vs sleeve gastrectomy for type 2 diabetes mellitus: a randomized controlled trial. Arch Surg. 2011;146(2):143–8.
Sumithran P, Prendergast LA, Delbridge E, et al. Long-term persistence of hormonal adaptations to weight loss. N Engl J Med. 2011;365(17):1597–604.
Kashyap SR, Bhatt DL, Schauer PR. STAMPEDE Investigators. Bariatric surgery vs. advanced practice medical management in the treatment of type 2 diabetes mellitus: rationale and design of the Surgical Therapy And Medications Potentially Eradicate Diabetes Efficiently trial (STAMPEDE). Diabetes Obes Metab. 2010;12(5):452–4.
Melissas J. IFSO guidelines for safety, quality, and excellence in bariatric surgery. Obes Surg. 2008;18(5):497–500.
de Hollanda A, Ruiz T, Jiménez A, et al. Patterns of weight loss response following gastric bypass and sleeve gastrectomy. Obes Surg. 2015;25(7):1177–83.
O’Brien PE, McPhail T, Chaston TB, et al. Systematic review of medium-term weight loss after bariatric operations. Obes Surg. 2006;16(8):1032–40.
Gracia-Solanas JA, Elia M, Aguilella V, et al. Metabolic syndrome after bariatric surgery. Results depending on the technique performed. Obes Surg. 2011;21(2):179–85.
Schmid H, Goelzer Neto CF, Dias LS, et al. Metabolic syndrome resolution by Roux-en-Y gastric bypass in a real world: a case control study. Rev Assoc Med Bras (1992). 2015;61(2):161–9.
Zambon S, Romanato G, Sartore G, et al. Bariatric surgery improves atherogenic LDL profile by triglyceride reduction. Obes Surg. 2009;19(2):190–5.
Malin SK, Bena J, Abood B, et al. Attenuated improvements in adiponectin and fat loss characterize type 2 diabetes non-remission status after bariatric surgery. Diabetes Obes Metab. 2014;16(12):1230–8.
Ahima RS, Sabri A. Bariatric surgery: metabolic benefits beyond weight loss. Gastroenterology. 2011;141(3):793–5.
Peterli R, Wölnerhanssen B, Peters T, et al. Improvement in glucose metabolism after bariatric surgery: comparison of laparoscopic Roux-en-Y gastric bypass and laparoscopic sleeve gastrectomy: a prospective randomized trial. Ann Surg. 2009;250(2):234–41.
Schumann R, Shikora SA, Sigl JC, et al. Association of metabolic syndrome and surgical factors with pulmonary adverse events, and longitudinal mortality in bariatric surgery. Br J Anaesth. 114(1):83–90.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
The study was approved by the appropriate Ethics Committee.
Grant Information
The authors have no financial relationships relevant to this article to disclose.
Conflict of Interest
The authors declare that they have no conflict of interest.
Ethical Approval
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.
Informed Consent
Informed consent was obtained from all individual participants included in the study.
Rights and permissions
About this article
Cite this article
Menguer, R.K., Weston, A.C. & Schmid, H. Evaluation of Metabolic Syndrome in morbidly Obese Patients Submitted to Laparoscopic Bariatric Surgery: Comparison of the Results between Roux-En-Y Gastric Bypass and Sleeve Gastrectomy. OBES SURG 27, 1719–1723 (2017). https://doi.org/10.1007/s11695-017-2547-3
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11695-017-2547-3